The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...

Following a filing revealing its intent to go public in the US on 6 January, artificial pancreas maker Beta Bionics has now ...

The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...

Underwriters have a 30-day option to purchase extra 1.13 million shares from present owners at IPO price. Beta Bionics will ...

Formed in 2019, Sionna's most recent financing was a $182 million third round that closed last year, which followed a $111 ...

Aardvark said it applied to list on the Nasdaq Global Market under the symbol AARD. The company didn't give an expected size for its IPO, nor did it offer an expected price range. Morgan Stanley, B of ...

Skadden, Latham, Kirkland and Davis Polk—traditionally the strongest legal advisers for major U.S. listings by Chinese companies—acted on fewer than five of these IPOs last year, according to a ...

The country’s top pork processor reveals the size and price range of its long-rumored separation from China’s WH Group, but a ...

Beta Bionics (BBNX), a maker of insulin delivery devices, has disclosed terms for an upsized $113M initial public offering.

The U.S. IPO market had a strong 2024 when compared with recent years, and when compared with the rest of the world.

Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the ...